BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

58.51 +1.02 (+1.77%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

19 20 Next >

Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals ↗

May 17, 2023

The company is working on a treatment for PKU, a disorder that can lead to intellectual disabilities.

Via Investor's Business Daily

Death Cross Looms Over Biomarin Pharmaceutical Investors ↗

May 02, 2023

Via Benzinga

What 17 Analyst Ratings Have To Say About Biomarin Pharmaceutical ↗

April 27, 2023

Via Benzinga

A Preview Of Biomarin Pharmaceutical's Earnings ↗

April 25, 2023

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 20, 2023

Via Benzinga

7 Biotech Stocks That Could Cure Your Portfolio Woes ↗

April 19, 2023

If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.

Via InvestorPlace

Where Biomarin Pharmaceutical Stands With Analysts ↗

March 21, 2023

Via Benzinga

Preview: Biomarin Pharmaceutical's Earnings ↗

February 24, 2023

Via Benzinga

Analyst Ratings for Biomarin Pharmaceutical ↗

February 22, 2023

Via Benzinga

BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst ↗

January 30, 2023

Via Benzinga

BioMarin Pharmaceutical Stock Shows Rising Relative Strength ↗

March 30, 2023

BioMarin Pharmaceutical stock had its Relative Strength Rating upgraded to 77 on Thursday, up from 70 a day earlier.

Via Investor's Business Daily

3 "Expensive" Growth Stocks That Are a Lot Cheaper Than You Realize ↗

March 28, 2023

The nosebleed trailing-12-month price-to-earnings ratios for these supercharged growth stocks fails to tell the full story.

Via The Motley Fool

BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74 ↗

March 21, 2023

A Relative Strength Rating upgrade for BioMarin Pharmaceutical shows improving technical performance. Will it continue?

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 ↗

March 21, 2023

Via Benzinga

What 5 Analyst Ratings Have To Say About Biomarin Pharmaceutical ↗

January 30, 2023

Via Benzinga

Why did Sarepta Therapeutics Stock Plummet?

March 21, 2023

SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.

Via MarketBeat

After FDA Delays Hemophilia Gene Therapy, BioMarin's Dwarfism Drug Under FDA Review For Expanded Use ↗

March 08, 2023

Via Benzinga

Why BioMarin Shares Are Plunging Today? ↗

March 06, 2023

Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the competition.

Via Benzinga

BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study ↗

March 06, 2023

The company is testing a drug for children with achondroplasia, a cause of dwarfism.

Via Investor's Business Daily

Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating ↗

March 03, 2023

On Friday, Kala Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 83, up from 67 a day earlier.

Via Investor's Business Daily

uniQure Stock Trying To Close In On Key Technical Measure ↗

February 28, 2023

uniQure stock had its Relative Strength Rating upgraded to 79 Tuesday -- a nice improvement, but still shy of the 80-plus desired score.

Via Investor's Business Daily

BioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023 ↗

February 28, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023 ↗

February 22, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 ↗

February 21, 2023

Via Benzinga

Earnings Scheduled For February 27, 2023 ↗

February 27, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.

Via Benzinga

3 Prime Healthcare Takeover Targets ↗

February 14, 2023

These three companies are attractive targets for their potential.

Via The Motley Fool

Moderna Stock Getting Closer To Key Technical Benchmark ↗

February 10, 2023

On Friday, biotech Moderna stock received an upgrade to its Relative Strength (RS) Rating, to 72 from 69 a day earlier.

Via Investor's Business Daily

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results ↗

February 03, 2023

Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony...

Via Benzinga

3 Drug Stocks With Promising Pipelines for 2023 ↗

January 23, 2023

These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023 ↗

January 30, 2023

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.